David Feinberg joined Cerner last year.  Cerner then was subsequently acquired by Oracle.  Oracle's founder and executive chairman, Larry Ellison, touts that Cerner is seeking to build a national EMR.  What does it all mean?  This episode takes a guess.    

Mark Cuban's "Cost Plus Drug Company" is on a mission to "disrupt the drug industry".  When a big name makes big promises the healthcare industry normally gets either excited or cringes.  However, I'm finding it's doing neither.  In this episode, we share some thoughts and opinions as to why that is.

Amazon's latest acquisition of One Medical is another example of the constant momentum it's bringing into healthcare.  I highlight how Amazon's entry into healthcare is showing greater potential than other non-healthcare players who are trying to break in.

While the healthcare community was chastising IBM for its Watson for Oncology solution last decade, what happened to the amazing healthcare data companies they acquired?  Well, they were set free this year, under the brand, Merative.  And what can we learn from the Watson Health days?

GE is in the process of splitting into three companies.  We explore why this is a good thing, and why it needs to be done.  

Jamil Rivers of Chrysalis Initiative talks outcome disparities within breast cancer, and striving to ensure every patient receives the care they deserve.

Donna Walthall of Dana Farber shares her ASCO observations as a fifteen-time attendee, celebrating Dana-Farber’s 75th anniversary

Tim Wolfe of Syapseshare their approach toward Real World Care and Applied Experience

Matthew Schulz, a Medical Science Liaison, shares his observations on this year’s ASCO session.

Chakra Chennubhotlaand Dusty Majumdar of SpIntellx explore the possibilities of empowering researchers and clinicians to unravel the hidden connections in the tumor microenvironment through deep profiling cell-cell communication patterns and spatial relationships.